Skip to main content

Table 5 Relationship between human leucocyte antigen-DRB1 shared epitope homozygosity or heterozygosity and risk of anticyclic citrullinated peptide antibody or rheumatoid factor seropositivity

From: HLA-DRB1 shared epitope genotyping using the revised classification and its association with circulating autoantibodies, acute phase reactants, cytokines and clinical indices of disease activity in a cohort of South African rheumatoid arthritis patients

  Total cohort (n= 143) Blacks (n= 124)
  SS (n= 80) SX (n= 52) SS (n= 72) SX (n= 43)
  OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
RF 7.0 (1.8 to 26.6) 0.0059 6.3 (1.5 to 25.7) 0.0126 4.5 (1.0 to 19.5) 0.0537 4.1 (0.9 to 19.3) 0.0813
aCCP 10.2 (2.6 to 40.3) 0.0010 9.2 (2.2 to 38.9) 0.0028 7.1 (1.6 to 30.4) 0.0121 6.4 (1.4 to 30.1) 0.0223
  1. aCCP = anticyclic citrullinated peptide antibodies; HLA = human leucocyte antigen; RF = rheumatoid factor; SE = shared epitope; SS = homozygous for shared epitope allele; SX = heterozygous for shared epitope allele.